Prevalence of lipoprotein lipase mutation in patients with severe hypertriglyceridemia and the characteristic features of hypertriglyceridemic pancreatitis

Utku Erdem Soyaltın; Ayşe Bengu Kandemır Bozkurt; Asli Ece Solmaz; Gulden Hakverdı; Ilgin Yıldırım Sımsır

doi:10.19161/etd.1209062

EN TR

Prevalence of lipoprotein lipase mutation in patients with severe hypertriglyceridemia and the characteristic features of hypertriglyceridemic pancreatitis

Abstract

Aim: We conducted a retrospective study with the aim of determining the prevalence of lipoprotein lipase (LPL) mutation in patients with severe hypertriglyceridemia (HTG) and to study differences in characteristic features of HTG induced acute pancreatitis (AP). Materials and Methods: Seventy adults with a serum triglyceride (TG) level ≥500 mg/dL were included in the study. Baseline characteristics, LPL mutation and risk factors between those with and without HTG-AP were compared. Results: The mean age was 43 ± 12 years, and males accounted for 55.7%. Of the patients 35 had TG level <2000 mg/dL, and 35 patients had TG ≥2000 mg/dL. LPL mutation was found in 19 (27.1%) of the cases. The prevalence of AP was 67.1% (47 patients). Younger age, TG level, hemoglobin A1c (HbA1c) were significantly independent risk factors for the development of HTG-AP. When patients were divided into groups based on TG levels (group 1 with TG <2000 mg/dL, group 2 TG ≥2000 mg/dL) the prevalence of AP was significantly higher in group 2 (51.4% vs. 82.9%). Age and HbA1c lost their significance for development of AP. When the relationship between the frequency of AP and TG value was evaluated, the specificity of TG threshold value for developing AP was found to be 2235 mg/dL. There was no difference in prevalence of AP and TG level between mutation detected and undetected groups. Conclusion: There was no difference in prevalence of AP and TG level between variant detected and undetected groups. In contrast to the literature, higher levels of TG cut-off points to develop AP was determined.

Keywords

Şiddetli hipertrigliseridemili hastalarda lipoprotein lipaz mutasyon prevalansı ve hipertrigliseridemik pankreatitin karakteristik özellikleri

Öz

Amaç: Şiddetli hipertrigliseridemili (HTG) hastalarda lipoprotein lipaz (LPL) mutasyon prevalansını belirlemek ve LPL varyantı olan ve olmayan HTG kaynaklı akut pankreatitin (AP) karakteristik özelliklerindeki farklılıkları araştırmak amacıyla retrospektif bir çalışma amaçladık. Gereç ve Yöntem: Çalışmaya serum trigliserid (TG) düzeyi ≥500 mg/dL olan 70 yetişkin dahil edildi. HTG-AP'i olan ve olmayan olgular arasındaki temel özellikler, LPL mutasyonunu ve risk faktörleri karşılaştırıldı. Bulgular: Ortalama yaş 43 ± 12 idi ve erkekler çalışma popülasyonunun %55.7'sini oluşturuyordu. 35 hastada TG düzeyi <2000 mg/dL, 35 hastada TG ≥2000 mg/dL idi. 19 olguda (%27.1) LPL mutasyonu saptandı. AP prevalansı %67.1 (47 hasta) idi. Korelasyon analizinde genç yaş, TG düzeyi, hemoglobin A1c (HbA1c) HTG-AP gelişimi için anlamlı derecede bağımsız risk faktörleriydi. Hastalar TG düzeylerine göre iki gruba ayrıldığında (TG <2000 mg/dL olanlar grup 1, grup 2 TG ≥2000 mg/dL) AP prevalansı grup 2'de anlamlı olarak daha yüksekti (%51.4'e karşı %82.9), yaş ile HbA1c AP gelişimi için anlamsız saptandı. AP sıklığı ile TG değeri arasındaki ilişki değerlendirildiğinde, TG eşik değerinin pankreatit gelişimi için özgüllüğü 2235 mg/dL bulunmuştur. Mutasyon saptanan ve saptanamayan gruplar arasında AP ve TG prevalansı açısından fark saptanmamıştır. Sonuç: Varyant saptanan ve saptanmayan gruplar arasında AP ve TG düzeyi açısından fark yoktu. Literatürden farklı olarak, AP geliştirmek için daha yüksek seviyelerde TG kesme noktası belirlendi.

Anahtar Kelimeler

Kaynakça

DeFrances CJ, Podgornik MN. 2004 National Hospital Discharge Survey. Adv Data 2006;(371):1-19. PMID: 16703980.
Saharia P, Margolis S, Zuidema GD, Cameron JL. Acute pancreatitis with hyperlipemia: studies with an isolated perfused canine pancreas. Surgery 1977;82(1):60-7. PMID: 877857.
Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med 2014;25(8):689-94. doi: 10.1016/j.ejim.2014.08.008.
Havel RJ. Pathogenesis, differentiation and management of hyper-triglyceridemia. Adv Intern Med 1969;15:117-54. PMID: 4908616.
Burnett JR, Hooper AJ, Hegele RA. Familial Lipoprotein Lipase Deficiency. 1999 Oct 12 [updated 2017 Jun 22]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
Davidson MH, Toth PP, Maki KC. Familial lipoprotein lipase deficiency. Therapeutic Lipidology. Humana Press. Totowa, NJ. 2007:465-6.
Demacker PNM, Stalenhoef AFH. Familial lipoprotein lipase deficiency. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:465-6.
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(9):2969-89. doi: 10.1210/jc.2011-3213.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
Hegele RA. Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001;69(6):1161-77. doi: 10.1086/324647.
Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012;23(4):310-20. doi: 10.1097/MOL.0b013e3283555a7e.
Tenner S, Baillie J, DeWitt J, Vege SS, American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol 2013;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218.
Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99(22):2901-7. doi: 10.1161/01.cir.99.22.2901.
Wright WT, Young IS, Nicholls DP, Graham CA. Genetic screening of the LPL gene in hypertriglyceridaemic patients. Atherosclerosis 2008;199(1):187-92. doi: 10.1016/j.atherosclerosis.2007.10.029.
Monsalve MV, Henderson H, Roederer G, et al. A missense mutation at codon 188 of the human lipoprotein lipase geneis a frequent cause of lipoprotein lipase deficiency in persons ofdifferent ancestries. J Clin Invest 1990;86(3):728-34. doi: 10.1172/JCI114769.
Hata A, Ridinger DN, Sutherland SD, et al. Missense mutations in exon 5 of the human lipoprotein lipase gene: inactivation correlates with loss of dimerization. J Biol Chem 1992;267(8):20132-9. PMID: 1400331. doi: 10.1016/S0021-9258(19)88676-3.
Ooi EMM, Russell BS, Olson E, et al. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations. Arterioscler Thromb Vasc Biol 2012;32(2):459-66. doi:10.1161/ATVBAHA.111.238493.
Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol 2019;13(1):80-8. doi: 10.1016/j.jacl.2018.10.006.
Dron JS, Hegele RA. Polygenic influences on dyslipidemias. Curr Opin Lipidol 2018;29(2):133-43. doi: 10.1097/MOL.0000000000000482
Carr RA, Rejowski BJ, Cote GA, Pitt HA, Zyromski NJ. Systematic review of hypertriglyceridemia-induced acute pancreatitis: a more virulent etiology? Pancreatology 2016;16(4):469-76. doi: 10.1016/j.pan.2016.02.011.
Amblee A, Mohananey D, Morkos M, et al. Acute Pancreatitis in Patients with Severe Hypertriglyceridemia in a Multi-Ethnic Minority Population. Endocr Pract 2018;24(5):429-36. doi: 10.4158/EP-2017-0178.
Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011;10:157. doi: 10.1186/1476-511X-10-157.
Schaap-Fogler M, Schurr D, Schaap T, Leitersdorf E, Rund D. Long-term plasma exchange for severe refractory hypertriglyceridemia: a decade of experience demonstrates safety and efficacy. J Clin Apher 2009;24(6):254-8. doi: 10.1002/jca.20224.
Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019;34(3):171-354. doi: 10.1002/jca.21705.
Zhang XL, Li F, Zhen YM, Li A, Fang Y. Clinical Study of 224 Patients with Hypertriglyceridemia Pancreatitis. Chin Med J (Engl) 2015;128(15):2045-9. doi: 10.4103/0366-6999.161361

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Utku Erdem Soyaltın
Türkiye

Ayşe Bengu Kandemır Bozkurt
Türkiye

Asli Ece Solmaz
Türkiye

Gulden Hakverdı
Türkiye

Ilgin Yıldırım Sımsır ^*
Türkiye

Yayımlanma Tarihi

12 Aralık 2022

Gönderilme Tarihi

10 Nisan 2022

Kabul Tarihi

27 Eylül 2022

Yayımlandığı Sayı

Yıl 2022 Cilt: 61 Sayı: 4

DOI

https://doi.org/10.19161/etd.1209062

IZ

https://izlik.org/JA76ZH26LA

Kaynak Göster

RIS / Bibtex

Vancouver

1.Utku Erdem Soyaltın, Ayşe Bengu Kandemır Bozkurt, Asli Ece Solmaz, Gulden Hakverdı, Ilgin Yıldırım Sımsır. Prevalence of lipoprotein lipase mutation in patients with severe hypertriglyceridemia and the characteristic features of hypertriglyceridemic pancreatitis. ETD. 01 Aralık 2022;61(4):658-65. doi:10.19161/etd.1209062